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When two prion strains infect a single host, one strain can interfere with the ability of the other to cause
disease but it is not known whether prion replication of the second strain is also diminished. To further
investigate strain interference, we infected hamsters in the sciatic nerve with the long-incubation-period
transmissible mink encephalopathy (TME) agent DY TME prior to superinfection of hamsters with the
short-incubation-period HY TME agent. Increases in the interval between TME agent inoculations resulted in
an extension of the incubation period of HY TME or a complete block of the ability of the HY TME agent to
cause disease. The sciatic nerve route of inoculation gave the two TME strains access to the same population
of neurons, allowing for the potential of prion interference in the lumbar spinal cord. The ability of the DY
TME agent to extend the incubation period of HY TME corresponds with detection of DY TME PrPSc, the
abnormal isoform of the prion protein, in the lumbar spinal cord. The increased incubation period of HY TME
or the inability of the HY TME agent to cause disease in the coinfected animals corresponds with a reduction
in the abundance of HY TME PrPSc in the lumbar spinal cord. When the two strains were not directed to the
same populations of neurons within the lumbar spinal cord, interference between HY TME and DY TME did
not occur. This suggests that DY TME agent replication interferes with HY TME agent replication when the
two strains infect a common population of neurons.
Prion diseases are a group of emerging, transmissible, neuro-
degenerative diseases of humans and animals that are inevita-
bly fatal. Two cases of variant Creutzfeldt-Jakob disease
(vCJD) were identified in humans who received blood trans-
fusions from asymptomatic individuals who later developed
vCJD. These cases suggest that vCJD can be transmitted from
human to human via blood prior to the onset of clinical symp-
toms (27, 32). The recent identification of multiple PrPSc types
in vCJD brain tissue suggests that more than one prion strain
may be present in field isolates of vCJD (33). Passage of vCJD
agents between humans could result in further adaptation of
vCJD, resulting in a selection of prion strains that have in-
creased human pathogenicity.
The mechanism of prion adaptation is beginning to be
understood. Rodent transmission studies suggest that after
intraspecies transmission, prion strains are selected from a
mixture or from new strains that arose from a single strain
present in the original inoculum (16, 19, 22). Experimental
inoculation of individual animals with two prion strains has
allowed the biological parameters of strain selection to be
characterized. Experimental coinfection of mice with two prion
strains was first described with the long-incubation-period
scrapie agent strain 22C and the short-incubation-period
scrapie agent strain 22A (14). In these experiments, the long-
incubation-period strain (i.e., the blocking strain) 22C was
intracerebrally inoculated prior to intracerebral inoculation
(i.e., superinfection) of the 22A strain. If the two strains acted
independently, the 22A scrapie agent would be expected to
cause clinical disease and death of these animals well before
the 22C scrapie agent would cause disease. Although the mice
succumbed to the 22A strain, based on neuropathological fea-
tures, the incubation period until the onset of 22A clinical signs
was significantly longer than the incubation period for mice
inoculated with the 22A scrapie agent alone. Increasing the
time interval between the 22C and 22A scrapie agent inocula-
tions resulted in an increase in the incubation period of 22A
and even completely inhibited the ability of the 22A scrapie
agent to cause disease. This indicated that the blocking strain
could interfere with the ability of the superinfecting strain to
cause disease, but it is not known whether the blocking strain
could interfere with prion replication.
In the present study, we show that the drowsy strain of the
transmissible mink encephalopathy (TME) agent (DY TME)
can interfere with the hyper strain of the TME agent (HY
TME). Infection of the sciatic nerve with the DY TME agent
prior to superinfection of hamsters in the sciatic nerve with the
HY TME agent can extend the incubation period of the HY
TME agent or completely block the ability of the HY TME
agent to cause clinical disease. The sciatic nerve route of in-
oculation directed the two TME strains into the same popula-
tion of neurons, allowing for the identification of a potential
site of prion interference to the lumbar spinal cord. If the two
strains were not initially directed to the same populations of
neurons, interference between HY TME and DY TME did not
occur. The ability of the DY TME agent to extend the incu-
bation period or completely prevent the HY TME agent from
causing disease corresponds with a reduction in the accumu-
lation of the HY TME-specific abnormal isoform of the prion
protein, PrPSc, in the lumbar spinal cord. These findings sug-
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gest that prion interference is due to a strain-specific reduction
in prion replication.
MATERIALS AND METHODS
Animal inoculations. All procedures involving animals complied with the
Guide for the Care and Use of Laboratory Animals (30) and were approved by the
Creighton University institutional animal care and use committee. For these
studies, 10- to 11-week-old male Syrian golden hamsters (Harlan Sprague-Dawley)
were used. Sciatic nerve inoculations were performed as previously described (5).
Briefly, anesthesia was administered by an intraperitoneal injection of a keta-
mine-xylazine mixture (120 mg of ketamine/kg of body weight, 10 mg of xylazine/
kg), and the hamster was restrained on a small-animal retraction system (Fine
Science Tools, Foster City, CA). A small incision in the skin of the hind limb was
made, and the sciatic nerve was exposed at the popliteal fossa. One microliter
containing 105.2 intracerebral (i.c.) 50% lethal doses (LD50)/g HY TME agent,
103.1 i.c. LD50/g DY TME agent, or 10% (wt/vol) 10,000-molecular-weight an-
ionic fixable Alexa Fluor 488-conjugated dextran (Molecular Probes, Eugene,
OR) was slowly injected with a 30-gauge needle attached to a Hamilton syringe
under the perineurium of the sciatic nerve. The 30-gauge needle was recipro-
cated within the sciatic nerve 10 times to enhance the efficiency of prion infection
(5, 17). After inoculation, the wound was closed with surgical staples.
Clinical diagnosis and calculation of incubation period. Animals were ob-
served three times per week for the onset of neurological disease, as described
previously (8). A clinical diagnosis of HY TME was based on clinical signs of
ataxia and hyperexcitability, while clinical diagnosis of DY TME was based on
clinical signs of progressive lethargy. The incubation period was defined as the
number of days between the inoculation of the agent that resulted in clinical signs
and the onset of clinical signs.
Tissue collection. Hamsters were killed at selected time points or during the
clinical course of disease by CO2 asphyxiation in an animal holding chamber, as
recommended by the American Veterinary Medical Association Panel on
Euthanasia. Brains, brainstems, and spinal cords were collected as described
previously (5). The L4 to L6 lumbar spinal cord segments, containing the ventral
motor neuron (VMN) cell bodies whose axons project into the sciatic nerve, were
collected as previously described (5). The intervertebral disk between T6 and T7
and the intervertebral disk between T10 and T11 serve as the rostral and caudal
landmarks for lumbar spinal cord collection, respectively (5). The tissue was
either flash frozen for Western blot analysis or perfused for microscopy.
Tissue preparation and Western blot analysis. Brain and spinal cord material
was homogenized to 10% (wt/vol) by passage of the tissue through a 26-gauge
needle in Dulbecco’s phosphate-buffered saline (DPBS) without Ca or Mg
(Mediatech, Herndon, VA), followed by a 30-second incubation in a cup horn
sonicator (Fisher Scientific, Atlanta, GA). The tissue was diluted to 5% (wt/vol)
in DPBS containing 4 or 40 units of proteinase K (PK) (Roche Diagnostics
Corporation, Indianapolis, IN) and incubated at 37°C for 1 h with constant
agitation. The PK digestion was terminated by the addition of Pefablock SC
(Roche Diagnostics Corporation, Indianapolis, IN) to a final concentration of 1
mM. This digestion condition resulted in the detection of only the PK-resistant
population of PrPSc and in the digestion of the normal form of the prion protein,
PrPC (11). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and West-
ern blot analysis were performed as described previously (4) with the monoclonal
anti-PrP antibody 3F4 (Chemicon, Temecula, CA) or with the R30 antibody,
which is a polyclonal serum directed against bovine PrP sequence 89 to 103 (12).
To more clearly illustrate the differences in molecular weight or the antibody
binding properties of PrPSc, multiple animals are shown in each group. The
Western blot was developed with Pierce Supersignal West Femto maximum-
sensitivity substrate, according to the manufacturer’s instructions (Pierce, Rock-
ford, IL), and imaged on a Kodak 2000R imaging station (Kodak, Rochester,
NY). The quantification of PrPSc abundance and the comparison of PrPSc abun-
dance between samples was performed as described previously (5).
PrPSc immunohistochemistry. Immunodetection of PrPSc in the central ner-
vous system (CNS) was performed as previously described (4). Briefly, hamsters
were perfused intracardially with DPBS prior to perfusion with McLean’s para-
formaldehyde-lysine-periodate (PLP). The tissues were removed from the ani-
mal and immersion fixed in PLP for 5 to 7 h at room temperature, placed in 70%
(vol/vol) ethyl alcohol, and embedded in paraffin (36). Following rehydration of
the tissue sections (7 m), antigen retrieval was performed by incubation of the
sections in 95% formic acid (Sigma-Aldrich, St. Louis, MO) for 20 min at room
temperature. PrPSc was detected with the monoclonal anti-PrP antibody 3F4
(Chemicon, Temecula, CA) and visualized by the ABC-horseradish peroxidase
Elite staining method (Vector Laboratories, Burlingame, CA). The chromogen
was developed with 0.05% (wt/vol) diaminobenzidine (Sigma-Aldrich, St. Louis,
MO) in Tris-buffered saline containing 0.003% H2O2 and counter stained with
hematoxylin (Richard Allen Scientific, Kalamazoo, MI). A minimum of three
infected and two uninfected animals per group and a minimum of 80 tissue
sections of lumbar spinal cord per animal were examined. Microscopy was per-
formed with a Nikon i80 microscope (Nikon, Melville, NY), and images were
captured with a DigiFire camera and ImageSys digital imaging software (Soft
Imaging Systems GmbH).
Fluorescence microcopy of retrograde tracer. Hamsters (n  5) were injected
in the sciatic nerve with 1 l of a 10% (wt/vol) solution of 10,000-molecular-
weight lysine-fixable dextran conjugated to Alexa Fluor 488, sacrificed 2 weeks
postinjection, and perfused with DPBS followed by PLP fixative, as previously
described (4). The lumbar spinal cord was removed and immersed in 20%
(wt/vol) sucrose for 24 h prior to serial sectioning (60 m) of the entire lumbar
spinal cord (vertebral level, T10 to T13) on a freezing microtome. Microscopy
and imaging were performed as described above.
Statistical analysis. Linear regression and Mann-Whitney rank sum analyses
were performed with Prism 4.0 for Macintosh software (GraphPad Software,
Inc., San Diego, CA). Incubation period data and PrPSc abundance data from
hamsters infected with the HY TME and DY TME agents were compared with
a two-tailed Mann-Whitney rank sum test. A P value of 0.01 was used in all
comparisons to determine whether the two datasets were statistically different.
RESULTS
Prion strain interference following sciatic nerve inoculation.
We had previously shown that sciatic nerve inoculation of the
DY TME agent 30 or 60 days prior to sciatic nerve superin-
fection of hamsters with the HY TME agent did not extend the
incubation period of HY TME (2). Expanding on these previ-
ous studies, the DY TME agent was inoculated into the sciatic
nerve and, at 60, 90, or 120 days after DY TME agent infec-
tion, the hamsters were superinfected in the same sciatic nerve
with the HY TME agent. If no interaction between the DY
TME and HY TME agents occurred, then the HY TME agent
would be expected to cause clinical disease prior to the onset
of DY TME clinical signs. As outlined in Table 1, all five
hamsters inoculated with the DY TME agent 60 days prior to
superinfection of hamsters with the HY TME agent developed
clinical signs of HY TME with an incubation period of 78  3
days, which is not different (P  0.05) from the results for
control hamsters inoculated in the sciatic nerve with the HY
TME agent alone. Sciatic nerve inoculation of the DY TME
agent 90 days prior to sciatic nerve superinfection of hamsters
with the HY TME agent resulted in all six hamsters developing
clinical signs of HY TME with an incubation period of 90  7
days, which is 12 days longer than for control hamsters inocu-
lated with the HY TME agent alone (Table 1) (P  0.01).
Finally, sciatic nerve inoculation of the DY TME agent 120
days prior to sciatic nerve superinfection with the HY TME
agent resulted in all five hamsters developing clinical signs of
DY TME with an incubation period of 220  3 days, which was
not different (P  0.05) from the results for control hamsters
inoculated with the DY TME agent alone (Table 1). In the
120-day-interval group, the time between superinfection of
hamsters with the HY TME agent and the onset of DY TME
clinical signs was 100 days. This is 22 days past the incubation
period for hamsters inoculated with the HY TME agent alone
(Table 1). Western blot analysis of PK-digested brain homog-
enate indicated that animals with HY TME clinical signs had
corresponding HY TME-specific PrPSc (fastest-migrating
polypeptide, 21 kDa [Fig. 1, lanes 5 to 11]), and animals with
DY TME clinical signs had DY TME-specific PrPSc (fastest-
migrating polypeptide, 19 kDa [Fig. 1, lanes 3 to 4 and 12 to
13]), confirming the clinical diagnosis (Fig. 1). The abundance
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of PrPSc from the brains of coinfected hamsters was similar to
the levels in control hamsters (Fig. 1).
Western blot detection of DY TME PrPSc in the spinal cord.
The initial detection and spread of DY TME PrPSc in the
spinal cord after sciatic nerve inoculation was determined by
PrPSc Western blot analysis. Western blot analysis of PK-di-
gested spinal cord homogenate failed to detect PrPSc at 60 days
after DY TME agent infection, consistent with our previous
studies (2) (Fig. 2A). At 90 days after DY TME agent infec-
tion, PrPSc was detected in vertebral segments C5 to C7
through T10 to T13. The highest levels of PrPSc were in the
T10 to T13 vertebral segment, a result consistent with the DY
TME agent entering the CNS in the lumbar spinal cord fol-
lowing sciatic nerve inoculation (Fig. 2B). At 120 days after
DY TME agent infection, PrPSc was detected in the entire
length of the spinal cord (Fig. 2C). In each vertebral segment
examined, there was an increase in the PrPSc abundance in
hamsters inoculated with the DY TME agent at 120 days
postinfection compared to the level at 90 days postinfection
(Fig. 2B and C).
Differential detection of DY TME and HY TME PrPSc by
Western blot analysis. Western blot analysis of PK-digested (4
U/ml) HY TME- or DY TME-infected brain homogenates
with the anti-PrP monoclonal antibody 3F4 resulted in detec-
tion of HY TME and DY TME PrPSc (Fig. 3, lanes 1 and 2).
The levels of DY TME and HY TME PrPSc were similar, but
DY TME PrPSc migrated 1 to 2 kDa faster than HY TME
PrPSc (Fig. 3, lanes 1 and 2) (6). This difference in migration is
due to differences in the PK cleavage sites of HY TME and DY
TME PrPSc (7). To determine the abundance of HY TME and
DY TME PrPSc in the coinfected animals, we expanded on
TABLE 1. Clinical signs of and incubation periods for hamsters inoculated in the sciatic nerve with the DY TME agent prior to
superinfection of hamsters with the HY TME agent
First inoculation
Interval between
inoculations
(days)
Second
inoculation
Clinical
sign
PrPSc
migration
(kDa)
No. of hamsters
affected/no.
inoculated
Onset of clinical symptoms
(avg days postinfection  SD)a
After first
inoculation
After second
inoculation
DY TME agent 120 Mock DY TME 19 5/5 217  2 NA
Mock 120 HY TME agent HY TME 21 5/5 NA 78  2
DY TME agent 60 HY TME agent HY TME 21 5/5 138  3 78  3*
DY TME agent 90 HY TME agent HY TME 21 6/6 180  7 90  7†
DY TME agent 120 HY TME agent DY TME 19 5/5 220  3‡ 100  3
a NA, not applicable; *, incubation period similar to that for animals inoculated with the HY TME agent alone (P  0.05); †, incubation period longer than that for
animals inoculated with the HY TME agent alone (P  0.01); ‡, incubation period similar to that for animals inoculated with the DY TME agent alone (P  0.05).
FIG. 1. HY TME and DY TME strain-specific PrPSc properties
correspond with the clinical signs of disease in hamsters infected with
the DY TME agent at 60, 90, or 120 days prior to superinfection of
hamsters with the HY TME agent. In control animals inoculated with
only the HY TME agent (lanes 1, 5, and 6), the nonglycosylated PrPSc
polypeptide migrates at 21 kDa, compared to the 19-kDa migration of
PrPSc from control animals inoculated only with the DY TME agent
(lanes 2, 3, and 4). Migration of the 19- and 21-kDa nonglycosylated
PrPSc polypeptides is indicated to the left of the figure. UN, mock
inoculation; HY, HY TME agent; DY, DY TME agent.
FIG. 2. Abundance of PrPSc in the spinal cord following sciatic
nerve inoculation with the DY TME agent. Shown is PrPSc Western
blot analysis of spinal cord homogenates digested with PK at 60 (A), 90
(B), and 120 (C) days after DY TME infection of the sciatic nerve.
Cervical (C) and thoracic (T) vertebral spinal cord segments are indi-
cated at the top of the figure. The arrows at the left of the figure
indicate migration of the 29-kDa molecular mass marker.
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previous studies describing differences in antibody binding to
the HY TME and DY TME PrPSc polypeptides (6). To differ-
entiate HY TME PrPSc from DY TME PrPSc based on anti-
body binding, we used the R30 polyclonal serum. Western blot
analysis of 250-g equivalents of non-PK-digested HY TME or
DY TME agent-infected brain homogenate with R30 detected
PrPSc from each TME agent strain and PrPC (Fig. 3, lanes 3
and 4). Western blot analysis of HY TME or DY TME agent-
infected homogenates digested with PK (40 U/ml) using the
R30 antibody resulted in HY TME PrPSc detection (Fig. 3,
lane 6), but we were unable to detect DY TME PrPSc with the
R30 antibody (Fig. 3, lane 5), presumably due to the digestion
of the R30 epitope on the DY TME PrPSc molecule. Western
blot analysis of fivefold serial dilutions of DY TME (Fig. 3,
lanes 7 to 10) and HY TME (Fig. 3, lanes 11 to 14) agent-
infected brain homogenate with the 3F4 antibody resulted in
the detection of PrPSc in 2-g equivalents of both HY TME
and DY TME brain homogenates. Western blot analysis of HY
TME agent-infected brain homogenate with the R30 antibody
(Fig. 3, lanes 15 to 18) detected HY PrPSc in 2-g brain
equivalents, indicating that R30 has an ability to detect HY
PrPSc similar to that of 3F4. The presence of DY PrPSc did not
interfere with the ability of R30 to detect HY PrPSc (data not
shown).
PrPSc Western blot analysis of lumbar spinal cords from
hamsters inoculated in the sciatic nerve with the DY TME and
HY TME agents. To investigate the effects of DY TME agent
infection on the initial detection and rate of accumulation of
HY TME PrPSc in the lumbar spinal cord, hamsters were
inoculated in the right sciatic nerve with the DY TME agent
(experimental group) or with the same concentration of an
uninfected homogenate (control group) 90 days prior to su-
perinfection of hamsters in the right sciatic nerve with the HY
TME agent. At 4, 6, 8, and 10 weeks after HY TME agent
infection, three hamsters were sacrificed in the control group
and three animals were sacrificed in the experimental group.
Western blot analysis with the R30 antibody was performed on
500-g equivalents of PK-digested lumbar cord homogenate.
In both the control and experimental groups, HY TME PrPSc
was first detected at 6 weeks postinfection and the PrPSc abun-
dance increased through 10 weeks after HY TME superinfec-
tion (Fig. 4). At both 8 and 10 weeks after sciatic nerve super-
infection with the HY TME agent, the abundance of HY TME
PrPSc in the lumbar spinal cord from the control group was
greater than in the experimental group (Fig. 4). Linear regres-
sion analysis of the control group (r2  0.9997) from weeks 6
to 10 after HY TME agent superinfection indicated a zero
intercept of 5 weeks and 6 days and an HY TME PrPSc dou-
bling time of 4.3 days. In the experimental group, linear re-
gression analysis (r2  0.8941) from weeks 6 to 10 after HY
TME superinfection indicated a zero intercept of 6 weeks and
2 days and an HY TME PrPSc doubling time of 6.5 days. The
regression analysis indicated that sciatic nerve infection with
the DY TME agent at 90 days prior to sciatic nerve superin-
fection with the HY TME agent delayed the initial detection of
HY PrPSc in the lumbar spinal cord by 3 days and resulted in
a 51% reduction in the rate of HY PrPSc accumulation.
To determine whether the HY TME agent could establish
infection in the lumbar spinal cord in hamsters inoculated with
the DY TME agent 120 days prior to superinfection of ham-
sters with the HY TME agent, Western blot analysis of 250-g
equivalents of lumbar spinal cord with the 3F4 and R30 anti-
bodies was performed on animals at the terminal stage of
disease. In hamsters inoculated with the DY TME agent 120
days prior to sciatic nerve superinfection with the HY TME
agent, DY TME-specific PrPSc was detected in the lumbar
spinal cord with the 3F4 antibody (Fig. 3 and Fig. 5, lanes 5 and
6), suggesting that HY TME PrPSc levels were reduced. West-
ern blot analysis of the same tissues was performed with the
R30 antibody, and HY TME PrPSc was not detected (Fig. 5,
lanes 11 and 12). To confirm the failure to detect HY TME
PrPSc in the lumbar spinal cord from the 120-day coinfected
group, this experiment was repeated in its entirety, as de-
scribed above. In the control group inoculated with the HY
TME agent alone, we were able to detect HY PrPSc with the
3F4 antibody (Fig. 5, lanes 13 and14). In the experimental
group, we were unable to detect HY PrPSc in 250-g equiva-
lents of PK-digested lumbar spinal cord homogenate with the
R30 antibody (Fig. 5, lanes 17 and 18) but high levels of DY
FIG. 3. Detection and differentiation of HY TME and DY TME PrPSc by Western blot analysis. PK digestion of HY TME and DY TME PrPSc
results in DY TME PrPSc migrating 1 to 2 kDa faster than HY TME PrPSc with the 3F4 antibody (lanes 1 and 2). The R30 antibody epitope is
present on both HY TME and DY TME PrPSc prior to PK digestion (lanes 3 and 4). PK digestion removes the R30 epitope from DY TME PrPSc
(lane 5) but not from HY TME PrPSc (lane 6). The 3F4 antibody can detect similar levels of HY TME and DY TME PrPSc (lanes 7 to 14). The
R30 antibody can detect levels of HY TME PrPSc similar to those detected by the anti-PrP antibody 3F4 (lanes 11 to 18). Migration of the 19- and
21-kDa nonglycosylated PrPSc polypeptides is indicated to the left of the figure.
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TME PrPSc were identified with the 3F4 antibody (Fig. 5, lanes
15 and 16).
Based on the abundance of HY TME PrPSc in the lumbar
spinal cord from hamsters inoculated with the HY TME agent
alone (Fig. 5, lanes 7 to 8 and 13 to 14), there is a minimum of
a 100-fold reduction in HY TME PrPSc levels in hamsters that
were inoculated with the DY TME agent 120 days prior to
superinfection of hamsters with the HY TME agent (Fig. 3,
lanes 15 to 18, and Fig. 5, lanes 11 to 12 and 17 to 18). Western
blot analysis of the same tissue with the 3F4 antibody revealed
DY TME-specific PrPSc (Fig. 5, lanes 5, 6, 15, and 16). Due to
the presence of DY TME PrPSc in these tissues, an animal
bioassay would have a reduced ability to detect small amounts
of the HY TME agent (3). Therefore, it is not possible to
unequivocally demonstrate whether the HY TME agent is
present in the lumbar spinal cord.
Immunohistochemical detection of PrPSc in the lumbar
spinal cord. To further refine the locations of TME interfer-
ence, PrPSc immunohistochemistry was performed on lumbar
spinal cord from hamsters inoculated in the sciatic nerve with
either the DY TME or HY TME agent. In animals inoculated
in the sciatic nerve with the HY TME agent, HY PrPSc was first
detected at 2 weeks postinfection in the lumbar spinal cord
ipsilateral to the site of inoculation within the soma of VMNs
and in the surrounding neuropil (Fig. 6B and C). The location
and morphology of the cell types that contain HY PrPSc in the
lumbar cord at 2 weeks after HY TME agent infection were
similar to fluorescently labeled VMNs (Fig. 6A).
Following sciatic nerve inoculation of the DY TME agent,
PrPSc was not detected at 60 days postinfection in the lumbar
spinal cord, consistent with Western blot data (2) (Fig. 2A).
Using PrPSc immunohistochemistry, DY TME PrPSc was de-
tected at 90 days postinfection in the lumbar spinal cord, con-
sistent with Western blot data (Fig. 2B). Within the lumbar
spinal cord, DY TME PrPSc was detected in lamina IX, which
contains VMNs, and in the medial regions of laminae II, III,
FIG. 4. Sciatic nerve inoculation with the DY TME agent 90 days prior to sciatic nerve superinfection of hamsters with the HY TME agent
results in a reduction in HY TME PrPSc in the lumbar spinal cord. Shown are immunodetection of HY TME PrPSc in the lumbar spinal cord by
Western blotting with the R30 antibody (A and B) and quantification of HY TME PrPSc polypeptides at selected time points after HY TME agent
inoculation (C). (A) Control hamsters were inoculated in the sciatic nerve with an uninfected brain homogenate 90 days prior to sciatic nerve
inoculation with the HY TME agent. (B) In the experimental group, hamsters were inoculated with the DY TME agent 90 days prior to sciatic
nerve superinfection of hamsters with the HY TME agent. The arrow on left of the Western blot indicates the migration of the 29-kDa molecular
mass marker. UN, mock infection; HY, HY TME agent; DY, DY TME agent. (C) In control hamsters (squares), HY TME PrPSc levels were
significantly higher (P  0.01) at 8 and 10 weeks postinfection, as indicated by asterisks, than were the HY TME PrPSc levels in the experimental
group (circles). Bars at each time point represent standard deviations. Linear regression analyses of HY TME PrPSc abundance between 6 and 10
weeks after HY TME agent infection in the control group (dashed line) and in the experimental group (solid line) are indicated.
FIG. 5. Sciatic nerve inoculation with the DY TME agent 120 days prior to sciatic nerve superinfection of hamsters with the HY TME agent
results in a failure to detect HY TME PrPSc in the lumbar spinal cord at terminal disease. Shown is PrPSc Western blot analysis of lumbar spinal
cord homogenates (250-g equivalents) digested with PK from hamsters infected with the HY TME agent or the DY TME agent or from animals
inoculated with the DY TME agent 120 days prior to sciatic nerve superinfection of hamsters with the HY TME agent using the 3F4 or R30
antibody. Migration of the 19- and 21-kDa nonglycosylated PrPSc polypeptides is indicated to the left of the figure. UN, mock infection; HY, HY
TME agent; DY, DY TME agent. Lanes 1 to 12, experiment 1; lanes 13 to 18, experiment 2.
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IV, and X in the lumbar spinal cord ipsilateral to the site of
inoculation, where it was not detected in mock-infected ham-
sters (Fig. 6D and E and data not shown). At 120 days after
DY TME agent infection, PrPSc had spread to lamina V, ipsi-
lateral to the site of DY TME agent inoculation (data not
shown). The initial detection and spread of PrPSc in the lumbar
spinal cord was consistent with detection of PrPSc by Western
blotting (Fig. 2). These data are consistent with entry of the
HY TME and DY TME agents into the CNS via VMNs and
suggest a potential location for TME agent interference to
occur.
Prion strain interference in hamsters coinfected with the DY
TME agent in the right sciatic nerve and with the HY TME
agent in the left sciatic nerve. If DY TME agent replication,
ipsilateral to the site of inoculation, is responsible for dimin-
ishing the ability of the HY TME agent to cause disease, then
inoculation of the HY TME agent in the sciatic nerve con-
tralateral to DY TME agent inoculation should result in ani-
mals succumbing to HY TME with incubation periods similar
to those for animals inoculated with the HY TME agent alone.
To test this hypothesis, hamsters were either mock or DY
TME agent inoculated in the right sciatic nerve 90 or 120 days
prior to superinfection of hamsters with the HY TME agent in
the left (contralateral) sciatic nerve.
Hamsters inoculated with the DY TME agent in the right
sciatic nerve 90 days prior to left sciatic nerve (contralateral)
superinfection with the HY TME agent developed HY TME
clinical signs, and HY TME PrPSc was detected in the brain by
Western blotting (Table 2 and data not shown). The incubation
period for these animals was 77  3 days and was not signifi-
cantly different from that for control hamsters inoculated with
the HY TME agent alone (77  3 days; P  0.05). For ham-
sters inoculated with the DY TME agent in the right sciatic
nerve 120 days prior to left sciatic nerve (contralateral) super-
FIG. 6. Initial deposition of HY TME and DY TME PrPSc following sciatic nerve inoculation is in the VMNs of the lumbar spinal cord.
(A) Fluorescence microscopy of lumbar spinal cord ipsilateral to sciatic nerve injection of fluorescently tagged dextran. Dextran is specifically
transported to VMN cell bodies in spinal cord lamina IX. The insert depicts a single VMN cell body that is filled with the retrograde tracer.
(B) Low-power image of PrPSc immunohistochemistry from the lumbar spinal cord ipsilateral to the site of HY TME agent inoculation at 2 weeks
postinfection. (C) PrPSc immunohistochemistry of the boxed region in panel B of a VMN with extensive intrasomal HY TME PrPSc deposits in
lamina IX. (D) PrPSc immunohistochemistry of lumbar spinal cord lamina IX ipsilateral to the site of DY TME agent inoculation at 90 days
postinfection, indicating DY TME PrPSc deposition associated with VMNs. (E) PrPSc immunohistochemistry of lumbar spinal cord lamina IX
ipsilateral to mock inoculation of uninfected brain homogenate. Scale bars: panels A and B, 100 m; panel C, 25 m; panels D and E, 50 m.
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infection with the HY TME agent, all five animals developed
HY TME clinical signs and HY PrPSc was detected in the brain
by Western blotting (Table 2 and data not shown). The incu-
bation period for these animals was 77  11 days and was not
significantly different from that for control hamsters inoculated
with the HY TME agent alone (77  3 days; P  0.05). These
data are consistent with TME agent strain selection occurring
in the ipsilateral lumbar spinal cord.
DISCUSSION
DY TME agent infection of the sciatic nerve can either
extend the incubation period for hamsters superinfected with
the HY TME agent or completely block the ability of the HY
TME agent to cause clinical disease. The interval between DY
TME and HY TME agent inoculations determines the clinical
outcome of disease. This effect has been observed in mice and
hamsters intracerebrally or intraperitoneally coinfected with
strains of scrapie, TME, and CJD (2, 3, 13, 14, 28). This study
selectively measured HY TME and DY TME PrPSc in the CNS
of coinfected animals based on their unique biochemical prop-
erties. In animals infected with the DY TME and HY TME
agents, detection of DY TME PrPSc corresponds with a reduc-
tion in HY TME PrPSc abundance and a corresponding in-
crease in the HY TME incubation period or a complete failure
of HY TME to cause disease. Since there is compelling evi-
dence to suggest that the abnormal isoform of the prion pro-
tein is the infectious agent in prion diseases, our data indicate
that the DY TME agent can interfere with HY TME agent
replication (10, 26, 34).
The ability of the DY TME agent to extend the incubation
period for hamsters superinfected with the HY TME agent
corresponded with the detection of DY TME PrPSc in the
lumbar spinal cord. This finding extends the results of previous
studies by demonstrating that the prion strain that was inocu-
lated first (i.e., the blocking strain) must be able to replicate to
have an effect on the subsequently inoculated prion strain (2,
18, 35). The initial detection of DY TME PrPSc and the in-
crease in abundance of DY TME PrPSc corresponded with the
ability of the DY TME agent to interfere with the HY TME
agent. The evidence in this and other animal models of prion
disease is in contrast to a cell culture model of prion strain
coinfection, wherein detection of PrPSc does not correspond
with the ability of the blocking strain to affect the superinfect-
ing strain (31). While the reason for this discrepancy is not
known, it could be due to host and strain differences between
these model systems.
DY TME agent replication can reduce, or possibly block,
HY TME agent replication in the CNS. A 90-day interval
between DY TME agent infection and superinfection of ham-
sters with the HY TME agent resulted in animals succumbing
to HY TME agent infection with an incubation period greater
than animals inoculated with the HY TME agent alone. In this
group of coinfected animals, HY PrPSc is first detected in the
lumbar spinal cord at the same time point after HY TME
agent infection as animals infected with the HY TME agent
alone. These data suggest that prior infection with the DY
TME agent does not affect the transport of the HY TME agent
from the site of inoculation in the sciatic nerve to VMNs in the
lumbar spinal cord, indicating that the sciatic nerve would not
be a location of prion strain interference. The reduced rate of
HY PrPSc accumulation in the lumbar spinal cord of hamsters
first inoculated with the DY TME agent suggests that DY
TME agent replication interferes with HY TME agent repli-
cation. Similarly, the inability to detect HY PrPSc in the lumbar
spinal cord in the 120-day-interval coinfected group suggests
that DY TME agent replication blocks HY TME agent repli-
cation. Since Western blot analysis measures PrPSc abundance
only, it is possible that prior infection with the DY TME agent
increases the clearance of HY PrPSc or prevents its spread to
second-order neurons within the lumbar spinal cord. Irrespec-
tive of the precise mechanism of interference involved, the
reduction in HY TME PrPSc abundance predicts the observed
increase in incubation period of HY TME in the 90-day-inter-
val group and the ability of the DY TME agent to cause
disease in the 120-day-interval group.
The results of this study indicate that prion interference
occurs in neurons located in the CNS. Prion interference oc-
curred in the lumbar cord ipsilateral to the site of inoculation,
based on data from Western blot analyses of the lumbar spinal
cords of coinfected animals and from coinfection experiments
in which both the right and left sciatic nerves were inoculated.
Further narrowing of the location of prion interference is
based on the known neuroanatomical pathways that the HY
TME and DY TME agents utilize following sciatic nerve in-
oculation. The HY TME agent is transported within the CNS
via three descending motor tracts (5). These motor tracts ei-
ther directly synapse on VMNs or synapse on interneurons that
TABLE 2. Clinical signs of and incubation periods for hamsters inoculated in the right sciatic nerve with the DY TME agent prior to
superinfection in the left sciatic nerve with the HY TME agent
First inoculation
(right sciatic nerve)
Interval between
inoculations
(days)
Second inoculation
(left sciatic nerve) Clinical sign
PrPSc
migration
(kDa)
No. of hamsters
affected/no.
inoculated
Onset of clinical symptoms
(avg days postinfection  SD)a
After first
inoculation
After second
inoculation
Mock 90 HY TME agent HY TME 21 5/5 NA 77  3
DY TME agent 90 HY TME agent HY TME 21 5/5 167  3 77  3*
DY TME agent 90 Mock DY TME 19 5/5 229  3 NA
Mock 120 HY TME agent HY TME 21 5/5 NA 73  3
DY TME agent 120 HY TME agent HY TME 21 5/5 197  11 77  11
DY TME agent 120 Mock DY TME 19 4/4 232  4 NA
a NA, not applicable; *, incubation period similar to that for animals inoculated with the HY TME agent alone (P  0.05).
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in turn synapse on VMNs of the lumbar spinal cord (1, 9, 23,
24). Consistent with this finding, HY TME PrPSc is first de-
tected in VMNs of the lumbar spinal cord ipsilateral to the site
of inoculation. DY TME PrPSc is also detected in similar
populations of neurons in the lumbar spinal cord. Based on
these data, a possible location for prion interference is within
VMNs in the lumbar spinal cord ipsilateral to the site of inoc-
ulation.
In natural prion diseases with an infectious etiology, it is not
known whether hosts are infected with prions a single time or
if multiple prion infections occur. However, the mechanisms of
prion adaptation following a single prion infection or multiple
prion infections are likely similar, based on the following evi-
dence. The interval between prion inoculation and the initial
detection of prion replication, the “zero phase,” can be ex-
tended by inoculation with a lower dose of prions (20, 21) (Fig.
7A). Once prion replication is detected, the rates of prion
replication are similar between high and low doses of prions
and the extension of the incubation period of the lower dose of
prions compared to higher doses is due to an extension of the
zero phase (20, 21) (Fig. 7A). In addition, the rate of prion
replication and the accumulation of PrPSc can differ between
prion strains (25, 29) (Fig. 7A). The ability of the blocking
strain to interfere with replication of a superinfecting prion
strain is dependent on replication of the blocking strain in a
location that is infected by both prion strains (2, 18, 35). The
critical parameter for prion strain interference is not whether
two prion strains are inoculated at the same time or separately
but when and where prion replication occurs. For example,
when a low dose of a quickly replicating short-incubation-
period strain (Fig. 7B, fast strain) is inoculated at the same
time as a high dose of a slowly replicating long-incubation-
period strain (Fig. 7B, slow strain), the onset of prion replica-
tion of the slow strain occurs prior to replication of the fast
strain (Fig. 7B). If common sites of infection are used by both
strains, this situation can lead to an extension of the incubation
period of the fast strain or a complete blockage of the fast
strain by the slow strain (15). Similarly, the same relative time
to onset of replication of the fast and slow strains can occur
when a high dose of the slowly replicating long-incubation-
period strain is inoculated first (Fig. 7C, slow strain) and at a
later time point the host is infected (i.e., superinfection) with a
high dose of a rapidly replicating short-incubation-period
prion strain (Fig. 7C, fast strain). In this example, the slow
strain could interfere with the fast strain when both strains
were infected at the same time or when the slow strain was
inoculated prior to superinfection of the animal with the fast
strain.
Aside from gaining an understanding of the mechanism of
prion adaptation, deciphering the mechanism of how a prion
strain with a long incubation period and low pathogenicity can
interfere with the replication of a short-incubation-period
highly pathogenic strain to cause disease is of great interest.
The ability to mimic this process in the absence of prion in-
fection could reduce prion replication in the CNS and serve as
a possible therapy.
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